6307-64-8

Basic information

• Product Name: 2,3-di(morpholin-4-yl)quinoxaline
• Synonyms: 2,3-Di(morpholin-4-yl)quinoxaline; 2,3-Di-morpholin-4-yl-quinoxaline; Quinoxaline, 2,3-di-4-morpholinyl-
• CAS NO: 6307-64-8
• Molecular Formula: C₁₆H₂₀N₄O₂
• Molecular Weight: 300.3556
• Mol File: 6307-64-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 512.9°C at 760 mmHg
• Flash Point: 264°C
• Density: 1.269g/cm³
• Vapor Pressure: 1.24E-10mmHg at 25°C
• Refractive Index: 1.627
• CAS DataBase Reference: 2,3-di(morpholin-4-yl)quinoxaline(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-di(morpholin-4-yl)quinoxaline(6307-64-8)
• EPA Substance Registry System: 2,3-di(morpholin-4-yl)quinoxaline(6307-64-8)

Safety Data

• Hazardous Substances Data: 6307-64-8(Hazardous Substances Data)

Usage

Heterocyclic organic compound

The compound contains a quinoxaline ring and two morpholine groups, making it a complex organic molecule with potential applications in various fields.

Quinoxaline ring

A heterocyclic aromatic ring system consisting of two fused six-membered rings with one nitrogen atom in each ring, contributing to the compound's chemical properties and potential applications.

Morpholine groups

Two morpholine groups (a five-membered heterocyclic ring with one oxygen and four carbon atoms) are attached to the 2 and 3 positions of the quinoxaline ring, contributing to the compound's unique properties.

Potential applications

2,3-di(morpholin-4-yl)quinoxaline has been studied for its potential applications in medicinal chemistry and material science, making it a versatile compound.

Biological activities

The compound exhibits promising biological activities, such as anticancer, antitubercular, and antiprotozoal properties, making it a potential candidate for drug development.

Building block for synthesis

Due to its unique structural features, 2,3-di(morpholin-4-yl)quinoxaline is a valuable building block for the synthesis of complex organic molecules and functional materials, contributing to its potential applications in the materials industry.

Upstream product

• 110-91-8 morpholine 
• 75163-15-4 2-chloro-3-(phenylethynyl)quinoxaline 
• 23719-78-0 2,3-dibromo-quinoxaline 
• 2213-63-0 2,3-dichloroquinoxaline 

Relevant articles and documents

Activities of quinoxaline, nitroquinoxaline, and [1,2,4]triazolo [4,3-a]quinoxaline analogs of mmv007204 against schistosoma mansoni

The reliance on one drug, praziquantel, to treat the parasitic disease schistosomiasis in millions of people a year shows the need to further develop a pipeline of new drugs to treat this disease. Recently, an antimalarial quinoxaline derivative (MMV007204) from the Medicines for Malaria Venture (MMV) Malaria Box demonstrated promise against Schistosoma mansoni. In this study, 47 synthesized compounds containing quinoxaline moieties were first assayed against the larval stage of this parasite, newly transformed schistosomula (NTS); of these, 16 killed over 70% NTS at 10mM. Further testing against NTS and adult S. mansoni yielded three compounds with 50% inhibitory concentrations (IC50s) of#0.31mM against adult S. mansoni and selectivity indices of$8.9. Administration of these compounds as a single oral dose of 400mg/kg of body weight to S. mansoni-infected mice yielded only moderate worm burden reduction (WBR) (9.3% to 46.3%). The discrepancy between these compounds' good in vitro activities and their poor in vivo activities indicates that optimization of their pharmacokinetic properties may yield compounds with greater bioavailabilities and better antischistosomiasis activities in vivo.

Electrochemical reduction of quinoxalinoquinoxaline

The electrochemical reduction of quinoxalinoquinoxaline gives fluoflavine (2) the structure of which is discussed.The electrochemical reduction of fluoflavine in acidic medium leads to a hexahydroquinolinoquinoxaline.A reduction mechanism is proposed based on cyclic voltammetry results and preparative electrolysis.The results obtained in the case of quinoxalinoquinoxaline are used to rationalize the results obtained in the case of pyrazinopyrazines and pyrazinoquinoxalines.